Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

• Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation.
  
• Additional posters representing an expansive body of data demonstrating the potential of Werewolf’s PREDATOR platform and INDUKINE product candidates will also be presented.
• Company to host conference call and webcast to review WTX-124 initial clinical results November 3, 2023, at 8:30 am ET
  

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that a poster describing interim first-in-human clinical results from initial monotherapy dose-escalation cohorts in the ongoing Phase 1/1b study of WTX-124 will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38^th Annual Meeting, taking place November 1-5, 2023 in San Diego, California. Additional posters with preclinical data supporting the PREDATOR platform and INDUKINE product candidates will also be presented at the meeting.

“At SITC, we look forward to sharing first-in-human clinical results from our lead candidate, WTX-124, including initial assessments of safety, pharmacokinetics, relevant biomarkers and preliminary antitumor activity from the ongoing monotherapy dose-escalation portion of our Phase 1/1b study in solid tumors. These data will provide early insight into the profile of WTX-124 and preferential activation through our INDUKINE design, including additional data since the abstract submission in June,” said Randi Isaacs, M.D., Chief Medical Officer of Werewolf. “Several preclinical abstracts were also accepted for poster presentation, collectively reinforcing distinct immune activating potential of our INDUKINE molecules across various mechanisms, including IL-2, and as a complement to other anti-cancer approaches, including checkpoint inhibitors and cell therapy.”